Details
Stereochemistry | RACEMIC |
Molecular Formula | C30H32Cl3NO |
Molecular Weight | 528.94 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C3=CC=C(Cl)C=C3\C2=C\C4=CC=C(Cl)C=C4
InChI
InChIKey=DYLGFOYVTXJFJP-MYYYXRDXSA-N
InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-
Molecular Formula | C30H32Cl3NO |
Molecular Weight | 528.94 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:27:25 UTC 2023
by
admin
on
Sat Dec 16 16:27:25 UTC 2023
|
Record UNII |
F38R0JR742
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
577
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
FDA ORPHAN DRUG |
895622
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.5.3.1 (ART/LUM)
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
NDF-RT |
N0000175482
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
WHO-ATC |
P01BF01
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
FDA ORPHAN DRUG |
245507
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/09/702
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1617
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
m6927
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | Merck Index | ||
|
7210
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
C81541
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
SUB08618MIG
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
F38R0JR742
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
7610
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
1370746
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
6437380
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
847728
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID3046663
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
204133-10-8
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
CHEMBL422330
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
C102070
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
UU-174
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
Lumefantrine
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
120583-69-9
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
SUPERSEDED | |||
|
Artemether and Lumefantrine
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
F38R0JR742
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
100000091055
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
DB06708
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
82186-77-4
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
156095
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | |||
|
LUMEFANTRINE
Created by
admin on Sat Dec 16 16:27:27 UTC 2023 , Edited by admin on Sat Dec 16 16:27:27 UTC 2023
|
PRIMARY | Description: A yellow crystalline powder.Solubility: Practically insoluble in water; soluble in dichloromethane R; slightly soluble in methanol R .Category: Antimalarial.Storage: Lumefantrine should be kept in a well-closed container.Additional information. Lumefantrine melts at 128?132?C.Definition: Lumefantrine contains not less than 98.5% and not more than 101.0% of C30H32Cl3NO, calculated with reference to the dried substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations
|
||
|
ENANTIOMER -> RACEMATE |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
In human liver microsomes and in recombinant CYP450 enzymes, lumefantrine was metabolized mainly by CYP3A4 to desbutyl-lumefantrine
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
LUMEFANTRINE Impurity A.
The impurity peaks are eluted at the following relative retention with reference to lumefantrine (retention time about 10 minutes): impurity A about 0.9.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
in patients with P. falciparum malaria |
|
||
Biological Half-life | PHARMACOKINETIC |
|
in healthy volunteers |
|
||
Tmax | PHARMACOKINETIC |
|
|
|||